ITA008

ITA008 is a monoclonal antagonist antibody currently in preclinical development by Immunoah Therapeutics. It is designed to target and block specific immune checkpoint pathways to enhance the body's immune response against cancer. As an antagonist antibody, its mechanism involves binding to inhibitory receptors on immune cells or their ligands on tumor cells, thereby preventing the suppression of T-cell activity and promoting an anti-tumor immune environment. Immunoah Therapeutics focuses on both agonist and antagonist modalities to address the limitations of current checkpoint inhibitors, particularly for patients who do not respond to standard therapies like PD-1 or CTLA-4 blockers.